                               SEQUENCE LISTING

<110> JOSLIN DIABETES CENTER, INC.
 
<120> METHODS AND COMPOSITIONS FOR TREATING METABOLIC DISORDERS

<130> M103021 1050WO

<140>
<141>

<150> 62/455,458
<151> 2017-02-06

<160> 14    

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 1
tttgggcatc accacgaaaa 20     


   
<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 2
ggacaccctc cagaaagcga 20 
    

<210> 3
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 3
ggagacctta ccacttgaag atg 23
                        


<210> 4
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 4
gcccggaacc tatctatcct ct 22 
             

<210> 5
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 5
accactcatg gatgaaagct aca 23    


<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 6
tcaggtagat tggctccaca g 21    


<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 7
cagtggactc cgatagcacg 20     


<210> 8
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 8
tgggacgact acagagccg 19  


<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 9
tccctggtgt acggctactg 20
    


<210> 10
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 10
atcttaaccc ggagtccttg a 21   


<210> 11
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 11
aggcttccag taccattagg t 21   


<210> 12
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 12
ctgagtgagg caaagctgat tt 22       


<210> 13
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 13
gcccagcaac attatccagt 20 


<210> 14
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 14
ggtcagactt cctgctacgc 20      


